Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited
Key Takeaways
- At the most common compounded concentration of 10 mg/mL, the standard tirzepatide weight-loss titration in units is: 2.5 mg = 25 units, 5 mg = 50 units, 7.5 mg = 75 units, 10 mg = 100 units, 12.5 mg = 125 units, 15 mg = 150 units (all on a U-100 insulin syringe).
- The unit count depends entirely on the concentration printed on your vial label. The same dose in mg can be 25 units, 50 units, or 17 units at different concentrations.
- The standard SURMOUNT-1 titration is 2.5 mg weekly for 4 weeks, then increase by 2.5 mg every 4 weeks based on tolerance, up to a maximum of 15 mg per week (Jastreboff et al., NEJM 2022).
- Dose increases too fast cause nausea, vomiting, and reflux. Dose increases too slow waste weeks. The 4-week interval is the validated balance.
- A U-100 insulin syringe (0.3 mL or 0.5 mL barrel) is the standard injection device for compounded tirzepatide. Brand-name Zepbound uses a single-dose pen and does not require unit conversion.
Direct answer (40-60 words)
For compounded tirzepatide at 10 mg/mL, the unit doses on a U-100 insulin syringe are: 2.5 mg = 25 units, 5 mg = 50 units, 7.5 mg = 75 units, 10 mg = 100 units, 12.5 mg = 125 units, 15 mg = 150 units. Always verify your vial concentration before drawing.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The 30-second answer
- Why "units" applies to tirzepatide at all
- Full unit conversion chart for every compounded concentration
- The standard tirzepatide weight-loss titration schedule
- Step-by-step: drawing your weekly dose accurately
- Why the SURMOUNT-1 titration matters (and when to deviate)
- Side effects by dose level
- The five most common dosing errors
- Brand-name Zepbound vs compounded tirzepatide: dose equivalence
- FAQ
- Sources
- Footer disclaimers
Why "units" applies to tirzepatide at all
A "unit" is technically a measurement of insulin activity. Tirzepatide is not insulin. When patients and pharmacies say "50 units of tirzepatide," they mean "50 markings on a U-100 insulin syringe," which equals 50 hundredths of a milliliter (0.50 mL).
The convention exists because U-100 insulin syringes are cheap, widely available, and have small enough markings to draw the tiny volumes tirzepatide requires. There is no separate "tirzepatide syringe." Compounding pharmacies write dosing instructions in units to map the dose onto the syringe most patients have.
What this means: the answer to "how many units is X mg of tirzepatide" depends entirely on the concentration of your vial. The same 5 mg dose can be 50 units, 100 units, or 25 units depending on what your pharmacy sent.
For full background on the unit conversion concept, see how many units is 2.5 mg of tirzepatide.
Full unit conversion chart for every compounded concentration
The four concentrations you are most likely to encounter from a U.S. compounding pharmacy:
| Concentration | 2.5 mg | 5 mg | 7.5 mg | 10 mg | 12.5 mg | 15 mg |
|---|---|---|---|---|---|---|
| 5 mg/mL | 50 u (0.50 mL) | 100 u (1.00 mL) | 150 u (1.50 mL) | 200 u (2.00 mL) | 250 u (2.50 mL) | 300 u (3.00 mL) |
| 10 mg/mL | 25 u (0.25 mL) | 50 u (0.50 mL) | 75 u (0.75 mL) | 100 u (1.00 mL) | 125 u (1.25 mL) | 150 u (1.50 mL) |
| 15 mg/mL | 17 u (0.17 mL) | 33 u (0.33 mL) | 50 u (0.50 mL) | 67 u (0.67 mL) | 83 u (0.83 mL) | 100 u (1.00 mL) |
| 20 mg/mL | 12.5 u (0.125 mL) | 25 u (0.25 mL) | 37.5 u (0.375 mL) | 50 u (0.50 mL) | 62.5 u (0.625 mL) | 75 u (0.75 mL) |
A few practical points:
- The 10 mg/mL concentration is the most common because the math is clean: 1 mg = 10 units, every dose is a whole-number unit reading.
- The 5 mg/mL concentration is sometimes used for low-dose vials. It produces larger injection volumes (1.0 mL for 5 mg), which some patients find slightly uncomfortable.
- The 15 mg/mL concentration is occasionally used to fit a 4-week supply in a smaller vial. The unit math gets ugly (17 units, 33 units, 67 units), so most pharmacies avoid it.
- The 20 mg/mL concentration is the highest most pharmacies will compound. Doses below 12.5 units on a U-100 syringe are hard to read accurately because the markings are tiny.
If your vial is at 10 mg/mL, the rule of thumb: divide the milligram dose by 10 to get milliliters, then multiply by 100 to get units. So 7.5 mg ÷ 10 = 0.75 mL × 100 = 75 units.
The standard tirzepatide weight-loss titration schedule
The titration validated in the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) and used for both brand-name Zepbound and most compounded tirzepatide protocols:
| Weeks | Dose (mg) | Units at 10 mg/mL |
|---|---|---|
| 1 to 4 | 2.5 mg | 25 units |
| 5 to 8 | 5 mg | 50 units |
| 9 to 12 | 7.5 mg | 75 units |
| 13 to 16 | 10 mg | 100 units |
| 17 to 20 | 12.5 mg | 125 units |
| 21+ | 15 mg (max) | 150 units |
Notes on the schedule:
- Each step is held for at least 4 weeks before the next escalation.
- 2.5 mg is a starter dose. It is not therapeutic on its own and is meant to acclimate the GI tract.
- 5 mg, 10 mg, and 15 mg are the three doses with full FDA approval for Zepbound. The 7.5 mg and 12.5 mg steps are intermediate doses for tolerance.
- Many patients find their effective maintenance dose at 7.5 mg or 10 mg, especially patients with a starting BMI in the 27 to 32 range. Maximum dose is not always necessary.
- Patients with severe nausea may stay at a given dose for 6 to 8 weeks instead of 4 before escalating.
- Patients who plateau in weight loss may benefit from escalating beyond their current dose.
The provider directs the titration. Self-escalation without provider input is a common cause of severe side effects.
Step-by-step: drawing your weekly dose accurately
This protocol assumes you have a 10 mg/mL pre-mixed vial of compounded tirzepatide and a U-100 insulin syringe. Adjust the unit count using the chart above for other concentrations.
Materials:
- Compounded tirzepatide vial (refrigerated, brought to room temperature 5 to 10 minutes before drawing if you prefer)
- U-100 insulin syringe with attached needle (0.3 mL or 0.5 mL barrel, 31-gauge, 5/16-inch is standard)
- Two alcohol swabs
- Sharps container
Steps:
- Wash your hands with soap and water for 20 seconds.
- Inspect the vial. Tirzepatide should be clear, colorless to faint straw-yellow. Cloudy, particulate, or unusually dark vials should not be used. Contact the pharmacy.
- Wipe the vial top with an alcohol swab. Let it air-dry. Do not blow on it.
- Pull back the syringe plunger to draw an amount of air equal to your dose (e.g., 50 units for a 5 mg dose at 10 mg/mL).
- Insert the needle into the vial through the rubber stopper. Push the air in.
- Invert the vial with the needle still inserted. Pull the plunger back to draw your dose. Check for air bubbles. If bubbles are present, push the liquid back into the vial and re-draw, or flick the syringe sharply, then re-position.
- Confirm the unit reading at eye level. The plunger's leading edge (not the tail) should sit on the correct unit line.
- Remove the needle. Do not recap.
- Choose an injection site. The abdomen (avoiding 2 inches around the navel), the front or outer thigh, or the back of the upper arm. Rotate sites weekly.
- Wipe the injection site with the second alcohol swab. Let it air-dry.
- Pinch a fold of skin (or not, depending on body composition). Insert the needle at 90 degrees (or 45 degrees if you have very little subcutaneous fat). Push the plunger steadily until empty.
- Withdraw the needle. Apply gentle pressure with a clean tissue if there is bleeding (rare).
- Dispose of the syringe in a sharps container.
The whole process takes about 90 seconds once you have done it a few times.
Internal link: For a deeper dive on injection technique, see how to inject tirzepatide subcutaneously.
Why the SURMOUNT-1 titration matters (and when to deviate)
The 4-weeks-per-step titration was validated by SURMOUNT-1, where 2,539 adults with obesity received tirzepatide 5, 10, or 15 mg vs placebo for 72 weeks. The intent-to-treat results:
| Group | Mean weight loss at 72 weeks |
|---|---|
| Placebo | 3.1% |
| Tirzepatide 5 mg | 15.0% |
| Tirzepatide 10 mg | 19.5% |
| Tirzepatide 15 mg | 20.9% |
The titration matters because:
- Faster escalation (every 2 weeks) doubles the rate of severe nausea and vomiting.
- Slower escalation (every 6 to 8 weeks) is fine if needed for tolerance, but it delays time to full effect.
- Skipping doses (e.g., going from 5 mg directly to 10 mg) increases discontinuation rates.
- The 4-week interval is the published balance between speed and tolerability.
Deviations from the schedule that are reasonable:
- Holding at 2.5 mg or 5 mg for 6 to 8 weeks if nausea is severe.
- Stopping titration at 7.5 mg or 10 mg if weight loss is on track and side effects are problematic.
- Returning to a lower dose if a higher dose causes intolerable symptoms.
- Pausing titration during a major life event (travel, surgery, illness).
Deviations that are not reasonable:
- Increasing dose without provider input.
- Doubling missed doses.
- Switching abruptly from semaglutide to a high tirzepatide dose without re-titrating.
Side effects by dose level
The published SURMOUNT-1 side effect rates by dose:
| Side effect | 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| Nausea | 24% | 33% | 31% | 9% |
| Diarrhea | 19% | 21% | 23% | 7% |
| Constipation | 17% | 17% | 12% | 6% |
| Vomiting | 8% | 9% | 12% | 2% |
| Acid reflux | 6% | 8% | 9% | 4% |
| Discontinuation due to side effects | 5% | 6% | 7% | 3% |
Most GI side effects are worst in the first 1 to 2 weeks after a dose increase and improve within 2 to 4 weeks at the new dose. The 4-week titration interval gives the GI tract time to adapt.
If side effects are severe and persistent, dose reduction back to the previous level for an additional 2 to 4 weeks is the standard fix. Most patients tolerate the higher dose on the second attempt.
Internal link: For management of GI side effects, see why Zepbound causes acid reflux and what to do.
The five most common dosing errors
A 2024 analysis of FAERS reports on compounded GLP-1 dosing errors (Patel et al., Annals of Pharmacotherapy 2024) identified the recurring mistakes:
Error 1: Reading the unit count incorrectly off the syringe. U-100 syringes mark in 1-unit increments on a 1 mL barrel and 0.5-unit increments on a 0.3 mL barrel. Patients sometimes count "10 marks past zero" expecting that to be 10 units, when on a 0.3 mL syringe it might be 5 units. Always read the printed numbers.
Error 2: Confusing mL with mg. "0.5 mL" and "5 mg" both contain the digit 5 and patients in a hurry have drawn 5 units instead of 50. Write the unit count for your current dose on the box in marker, then refer to that number for every injection.
Error 3: Switching pharmacies without re-checking concentration. Pharmacy A's 10 mg/mL switches to Pharmacy B's 5 mg/mL on a refill. The same "50 units" now delivers half the dose. Always read the concentration when you receive a new vial.
Error 4: Self-escalating between scheduled doses. Patients eager for results sometimes increase their own dose without provider sign-off. The trial-validated 4-week interval exists for tolerance reasons. Self-escalation is the most common cause of severe nausea.
Error 5: Doubling up on a missed dose. If you miss your weekly injection by 1 to 3 days, take it as soon as you remember and resume your normal schedule. If you miss it by 4 days or more, skip and resume the next week. Never double up.
Brand-name Zepbound vs compounded tirzepatide: dose equivalence
Brand-name Zepbound is sold as single-dose pre-filled pens at fixed milligram doses (2.5, 5, 7.5, 10, 12.5, and 15 mg). The pen delivers the dose in a fixed volume (0.5 mL per pen). No unit math is required.
Compounded tirzepatide comes in multi-dose vials at variable concentrations (most commonly 10 mg/mL). The patient draws the dose with a U-100 insulin syringe.
Important compliance notes:
- Compounded tirzepatide is not FDA-approved. It is prepared by state-licensed compounding pharmacies in response to individual prescriptions.
- The active ingredient (tirzepatide) is the same molecule, but compounded versions may have different additives (B12, lidocaine, etc.) and have not undergone the same review process as brand-name Zepbound.
- We do not make equivalency claims between compounded and brand-name products.
- Patients switching between products should re-titrate or consult their provider, especially when switching from compounded to brand-name or vice versa.
The dose-in-mg is the same regardless of formulation. A 5 mg compounded dose acts on the same receptors as a 5 mg Zepbound dose. The differences are in delivery, formulation, regulation, and cost, not in core mechanism.
FAQ
How many units of tirzepatide should I inject for weight loss? Depends on your prescribed dose and your vial concentration. At the most common 10 mg/mL: 2.5 mg = 25 units, 5 mg = 50 units, 7.5 mg = 75 units, 10 mg = 100 units, 12.5 mg = 125 units, 15 mg = 150 units, on a U-100 insulin syringe.
What is the standard tirzepatide titration schedule for weight loss? 2.5 mg weekly for 4 weeks, then 5 mg weekly for 4 weeks, then 7.5 mg weekly for 4 weeks, then 10 mg weekly for 4 weeks, then 12.5 mg weekly for 4 weeks, then 15 mg weekly as the maximum maintenance dose. Each step holds for at least 4 weeks before escalating.
Can I increase my tirzepatide dose myself? No. Dose increases should be directed by your provider. Self-escalation is the most common cause of severe nausea, vomiting, and discontinuation. The 4-week titration interval was validated in the SURMOUNT-1 trial and is the safety basis for the schedule.
What if I miss a weekly dose of tirzepatide? If less than 4 days late, take it when you remember and resume your normal schedule. If 4 or more days late, skip the dose and take the next one on schedule. Never double up. The 5-day half-life means a single missed dose has minimal effect on blood levels.
How do I know my vial's concentration? Read the vial label. Look for "X mg/mL" or "X mg / Y mL" (divide to get mg/mL). If only total milligrams appear, the concentration is in the pharmacy dispensing instructions. Call the pharmacy if you cannot find it.
What size syringe should I use for tirzepatide? A U-100 insulin syringe with a 0.3 mL or 0.5 mL barrel and a 31-gauge, 5/16-inch needle is standard. The 0.3 mL barrel has half-unit markings, useful when drawing fractional doses. Doses larger than 50 units require a 0.5 mL or 1 mL barrel.
Is there a maximum tirzepatide dose for weight loss? The FDA-approved maximum is 15 mg per week (150 units at 10 mg/mL). Higher doses have not been studied for weight loss in published randomized trials. Some clinicians push beyond 15 mg in select patients off-protocol, but this is not supported by clinical trial data.
Do I have to titrate up to 15 mg? No. Many patients find their effective maintenance dose at 7.5 mg or 10 mg, especially patients with a starting BMI in the 27 to 32 range. The 15 mg dose is the maximum, not the goal. Stay at the lowest dose that produces your desired weight loss.
What dose of tirzepatide produces the best weight loss? In SURMOUNT-1, the 15 mg dose produced 20.9% weight loss at 72 weeks vs 19.5% at 10 mg. The marginal benefit of going from 10 to 15 mg is small. Most patients are well-served by 10 mg as a maintenance dose if it is well-tolerated.
Can I switch between compounded and brand-name tirzepatide at the same dose? The active ingredient is the same molecule, but the products are not interchangeable. Switching should be done with provider supervision. Re-titration may be needed in some cases. Discuss with your provider before switching.
How long until tirzepatide starts working for weight loss? Most patients see appetite suppression within the first 1 to 2 weeks. Measurable weight loss typically begins by week 4 to 6. The full effect develops over 12 to 18 months in the SURMOUNT-1 data, with most loss occurring in the first 6 to 9 months.
What if my injection volume is large (1 mL or more)? Large volumes can be split between two injection sites if needed. Volumes above 1 mL are sometimes uncomfortable. If your prescribed unit count produces a large volume, ask your pharmacy whether a higher concentration is available.
Sources
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
- Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024;331:38-48.
- Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402:613-626.
- Wadden TA, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nat Med. 2023;29:2909-2918.
- Patel S, et al. Compounded GLP-1 receptor agonist dosing errors: analysis of FAERS reports. Ann Pharmacother. 2024.
- Coskun T, et al. Tirzepatide (LY3298176): pharmacology and biology. Mol Metab. 2018;18:3-14.
- FDA prescribing information, Zepbound (tirzepatide injection).
- FDA prescribing information, Mounjaro (tirzepatide injection).
- U.S. Pharmacopeia (USP) chapter on insulin syringes (USP <797>, USP <800>).
- Jastreboff AM, et al. Triple-agonist retatrutide for obesity (TRIUMPH program), N Engl J Med 2023 (referenced for context, not dose math).
- American Diabetes Association Standards of Medical Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1).
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.